The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 18, 2016

Filed:

Jul. 31, 2012
Applicants:

Navin K. Kapur, Hanover, MA (US);

Richard H. Karas, Franklin, MA (US);

Inventors:

Navin K. Kapur, Hanover, MA (US);

Richard H. Karas, Franklin, MA (US);

Assignee:

Tufts Medical Center, Inc., Boston, MA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 38/18 (2006.01); A61K 38/17 (2006.01); A61K 31/7088 (2006.01); C07K 16/22 (2006.01); A61K 31/713 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1841 (2013.01); A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 38/177 (2013.01); A61K 38/179 (2013.01); C07K 16/22 (2013.01); C07K 16/2896 (2013.01);
Abstract

Endoglin has now been shown to be an important target of therapy to reduce disease symptoms associated with heart failure, particularly cardiac fibrosis. Soluble Endoglin is identified as an anatogonist to TGFβ1 activity, while membrane-bound Endoglin is identified as a necessary component to promote TGFβ1 activity in heart failure. The present invention therefore features methods and kits for treatment of subject having heart failure or a related disorder by administering a composition that decreases TGFβ1 signaling through either direct inhibition of membrane-bound Endoglin or promoting expression of soluble Endoglin.


Find Patent Forward Citations

Loading…